IDEXX Laboratories, Inc. $IDXX Stock Holdings Decreased by Intech Investment Management LLC

Intech Investment Management LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,079 shares of the company’s stock after selling 342 shares during the period. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $2,553,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in IDXX. MorganRosel Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the first quarter worth approximately $26,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after acquiring an additional 30 shares in the last quarter. WPG Advisers LLC purchased a new position in shares of IDEXX Laboratories in the first quarter worth approximately $37,000. Bank of Jackson Hole Trust increased its position in shares of IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after acquiring an additional 69 shares in the last quarter. Finally, Retirement Wealth Solutions LLC increased its position in shares of IDEXX Laboratories by 40.0% in the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company’s stock worth $44,000 after acquiring an additional 30 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 4th. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, Leerink Partners boosted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.44.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 in the last three months. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $643.99 on Tuesday. The firm has a fifty day simple moving average of $605.56 and a 200-day simple moving average of $515.63. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The stock has a market capitalization of $51.52 billion, a price-to-earnings ratio of 53.62, a PEG ratio of 4.15 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the company earned $2.44 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.